MEDDEV 2.12-2 Post-Market Clinical Follow-up Guidance

PMCF stands for Post-Market Clinical Follow-Up. It is a continuous process used to collect and evaluate clinical data on a medical device after it is placed on the market. Under EU MDR, PMCF helps confirm safety and performance, identify emerging risks, verify benefit-risk acceptability, and determine whether clinical evaluation conclusions remain valid throughout the device lifecycle.

Post-market clinical follow-up covers the planned methods used to gather and assess clinical data after commercialization. This can include PMCF studies, registries, user surveys, literature reviews, complaint trend analysis, and follow-up of adverse events. It also includes documenting the rationale, methods, results, and conclusions in PMCF plans and evaluation reports that support the clinical evaluation and post-market surveillance system.

MEDDEV 2.12-2 treats PMCF as a generally expected part of post-market clinical evidence generation for many devices, especially where residual risks, long-term performance questions, novel technology, or limited premarket clinical data exist. Under EU MDR, manufacturers must justify the scope of PMCF based on device risk, maturity, claims, and available evidence, rather than assuming it can be omitted without a documented rationale.

A PMCF plan should define the objectives, clinical questions, methods, data sources, timelines, responsibilities, and criteria for evaluating results. It should explain why the selected PMCF activities are appropriate for the device and how outputs will feed into the CER, PMS reports, risk management, and benefit-risk assessment. A strong plan is device-specific, proportionate, and clearly justified.

PMCF is one of the key inputs into the Clinical Evaluation Report because it provides ongoing post-market clinical evidence. PMCF findings help confirm whether the device continues to perform as intended, whether residual risks remain acceptable, and whether new hazards or trends have emerged. The CER should reflect PMCF outputs, and inconsistencies between the two documents can raise concerns during review.

Literature review may contribute to PMCF, but it is not automatically sufficient on its own. Regulators and Notified Bodies expect the PMCF approach to be justified based on device-specific risk, novelty, claims, and available real-world data. In some cases, literature can support a proportionate PMCF strategy, but many devices require additional methods such as surveys, registries, complaint analysis, or clinical follow-up activities.

Common deficiencies include generic PMCF plans, weak justification for chosen methods, missing links to risk management and PMS, unclear clinical objectives, inadequate evaluation of collected data, and reports that do not support CER conclusions. Reviewers also frequently identify poor traceability between PMCF outputs and broader technical documentation, especially where complaint trends, vigilance data, or residual risks are not properly addressed.

Elexes helps manufacturers review PMCF adequacy, design proportionate PMCF strategies, strengthen PMCF plans and evaluation reports, and align outputs with CERs, PMS, and risk management files. The team also supports gap assessments, remediation, and broader EU MDR documentation alignment so manufacturers can present a coherent, defensible post-market clinical evidence package during Notified Body review.